2020
Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks
Asay B, Edwards B, Andrews J, Ramey M, Richard J, Podell B, Gutiérrez J, Frank C, Magunda F, Robertson G, Lyons M, Ben-Hur A, Lenaerts A. Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. Scientific Reports 2020, 10: 6047. PMID: 32269234, PMCID: PMC7142129, DOI: 10.1038/s41598-020-62960-6.Peer-Reviewed Original ResearchConceptsConvolutional neural networkNeural networkDeep convolutional neural networkHistopathological image analysisPulmonary pathologyTesting of novel therapiesAnimal modelsSemi-quantitative histopathology scoresImage recognitionUser limitationsNon-clinical animal modelsHistopathological imagesSeverity of diseaseTreatment of tuberculosisSoftware toolsTreatment cohortsNovel therapiesPulmonary tissueDisease progressionHistopathological analysisMouse modelPreclinical evaluationHistopathological scoresSuccessful treatmentPathological features
2019
Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development
Beites T, O’Brien K, Tiwari D, Engelhart C, Walters S, Andrews J, Yang H, Sutphen M, Weiner D, Dayao E, Zimmerman M, Prideaux B, Desai P, Masquelin T, Via L, Dartois V, Boshoff H, Barry C, Ehrt S, Schnappinger D. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature Communications 2019, 10: 4970. PMID: 31672993, PMCID: PMC6823465, DOI: 10.1038/s41467-019-12956-2.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAnimalsAntitubercular AgentsCallithrixDrug DevelopmentElectron TransportElectron Transport Complex IIIElectron Transport Complex IVGene Knockdown TechniquesImidazolesIn Vitro TechniquesLungMiceMycobacterium tuberculosisNADH DehydrogenasePiperidinesPyridinesTuberculosisTuberculosis, PulmonaryConceptsTuberculosis drug developmentDrug developmentTreatment of MtbDisease progressionMost lesionsOxidase inhibitorsClinical useType-2 NADH dehydrogenaseMycobacterium tuberculosisMiceRespiratory chainFatty acidsIntrinsic plasticityRespiratory enzymesInflammationClofazimineStandard growth mediumLesionsTuberculosis